 25. For subjects in the VMS Substudy only: use of medication that may affect the outcome of the vasomotor symptom endpoints within 28 days prior to Screening e.g. SSRIs selective serotonin reuptake inhibitors, SNRIs serotonin and norepinephrine reuptake inhibitors, aldomet, dopaminergic or antidopaminergic drugs, gabapentin, clonidine, or bellergal. 